Geographic Atrophy

Mary Beth Yackey, OD, and Michael Javaheri, MD, share their perspectives on the modernization of geographic atrophy identification and treatment.

The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.

Early detection of incipient geographic atrophy is critical to identify patients at greatest risk of progression and who may benefit most from newly approved complement inhibition therapies.

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene, the company stated in a news release.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

Since its U.S. launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.

The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.

The ANX007 global pivotal program is the first to use vision preservation as a primary outcome measure in GA.

Catch up on a few of the top stories from Modern Retina in 2023.

A study surveying retina specialists found surprising results in therapy preference.

Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.

An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.

A multicenter study in Japan examined patients to understand geographic atrophy characteristics and progression rate.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

The first approved GA treatment leaves room for additional therapies.

Optometry Times sat down with Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, to discuss his upcoming presentations at AAOpt.

This podcast provides a review of some of the key highlights from the Controversies in Modern Eye Care meeting held in April 2023. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Steven Ferrucci, OD, FAAO, discusses imaging techniques and treatment options for geographic atrophy as part of his AAOpt presentation alongside Carolyn Majcher, OD, FAAO.

According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.

The complement C5 inhibitor significantly reduced GA progression.

You may be wondering: What is all this hype about geographic atrophy (GA)? If you are, let us look at the enigma.

Arshad M. Khanani, MD, MA, FASRS, sat down with Optometry Times to discuss the recent FDA approval of avacincaptad pegol intravitreal solution for treatment of geographic atrophy.

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two phase 3 clinical trials.

Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).